作为医美行业的领军企业，爱美客通过一系列创新实践，既实现了自身的高质量发展，更引领了行业的 转型方向。未来，随着国际化布局的深化与新技术、新产品的持续落地，公司将继续以创新为核心驱动 力，持续辐射产业生态，为健康中国建设与全球医美行业的进步贡献更多力量。 以上实践取得了技术、行业与社会多方面的成果。公司核心产品市场占有率稳居前列，"濡白天使"作为 国家重点研发计划成果，累计产值已突破30亿元；2024年10月，医用含聚乙烯醇凝胶微球的交联透明质 酸钠凝胶（商品名：嗗科拉）获批，进一步丰富了高端产品线。产学研协同显著提升了公司竞争力与行 业整体水平。同时，公司于2025年获中国整形美容协会授予"2025中国医疗美容行业领袖企业奖"，体现 了对其行业引领地位与创新实力的肯定。在近3000亿元规模的中国医美市场中，爱美客带动行业从价格 竞争转向价值竞争，促进了规范化与高质量发展。在社会价值上，公司积极履行责任，2024年捐赠500 万元发起"幸福明天·新美妈妈"公益项目；2025年捐赠100万元驰援香港大埔火灾受灾同胞，践行"科技 向善"，让创新成果惠及民生。 爱美客（300896）是国内最早聚焦生物医用软组织修复 ...

Core Insights - AbbVie’s global aesthetics leader, Allergan Aesthetics, is driving unprecedented innovation in China's aesthetic industry, aiming to collaborate with local biotech firms and industry platforms to foster high-quality technologies and solutions from China [1][2] Group 1: Event Overview - The "China Innovation Collaboration Day" hosted by Allergan Aesthetics in Shanghai gathered leaders from the medical aesthetics industry, investment sector, and upstream innovation fields to discuss trends, R&D progress, commercialization, and industry investment [1] - The event featured the launch of the "AbbVie China Innovation Award (Aesthetics Award)," which aims to identify and empower early-stage technologies and projects in the medical aesthetics sector [1][2] Group 2: Innovation Award Details - The innovation award will select promising early-stage biotech companies and provide a support package valued at 500,000 yuan, including access to high-standard laboratories, office space, R&D team support, and professional advice on R&D, production, quality, and compliance [2] - Allergan Aesthetics emphasizes the importance of aligning technological breakthroughs with localized service systems, aiming to create a sustainable and replicable innovation model in China [2] Group 3: Future Development Plans - Allergan Aesthetics plans to maintain an open collaboration approach, adhering to global quality and scientific standards while supporting the cultivation and development of high-quality local innovation projects [2]